Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | HTT | P42858 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | ATM | Q13315 | 1/20 | 0.48 |
| ▸ | BCHE | P06276 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | LTA4H | P09960 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7145414 | 0.81 | CHRM2 (0.46) | HTTSMN1; SMN2CHRM2MEN1KMT2A | |
| SCHEMBL7215264 | 0.81 | LTA4H (0.63) | ALDH1A1HTTKDM4ESMN1; SMN2MEN1 | |
| SCHEMBL28857985 | 0.81 | CHRM2 (0.58) | ALDH1A1HTTKDM4ESMN1; SMN2CHRM2 | |
| SCHEMBL1279045 | 0.81 | HTT (0.73) | ALDH1A1HTTKDM4ESMN1; SMN2CHRM2 | |
| SCHEMBL1044325 | 0.81 | MEN1 (0.52) | KDM4ECHRM2MEN1KMT2ABCHE | |
| SCHEMBL121529 | 0.80 | CHRM2 (0.70) | ALDH1A1HTTKDM4ESMN1; SMN2CHRM2 | |
| SCHEMBL6635774 | 0.80 | SCN8A (0.53) | ALDH1A1HTTKDM4ESMN1; SMN2CHRM2 | |
| Hydrochloric Acid SCHEMBL2147064 | 0.78 | CHRM2 (0.68) | ALDH1A1HTTKDM4ESMN1; SMN2CHRM2 | |
| Hydrochloric Acid SCHEMBL9479560 | 0.78 | CHRM2 (0.68) | ALDH1A1HTTKDM4ESMN1; SMN2CHRM2 | |
| SCHEMBL2477823 | 0.75 | GAA (0.37) | ALDH1A1KDM4ESMN1; SMN2CHRM2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10065965-B2 | Imidazo[1,2-B][1,2,4]triazine derivatives as antiparasitic agents | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-09-04 | — | — | US | disclosed |
| US-20180141949-A1 | IMIDAZO[1,2-B][1,2,4]TRIAZINE DERIVATIVES AS ANTIPARASITIC AGENTS | THE UNIVERSITY OF DUNDEE (GB) | 2018-05-24 | — | — | US | disclosed |
| EP-3303336-A1 | IMIDAZO[1,2-B][1,2,4]TRIAZINE DERIVATIVES AS ANTIPARASITIC AGENTS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2018-04-11 | — | — | EP | disclosed |
| WO-2016193111-A1 | IMIDAZO[1,2-B][1,2,4]TRIAZINE DERIVATIVES AS ANTIPARASITIC AGENTS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2016-12-08 | — | — | WO | disclosed |
| EP-1641465-B1 | COMBINATIONS OF AN ARYL ANILINE BETA-2 ADRENERGIC RECEPTOR AGONIST AND A CORTICOSTEROID | THERAVANCE INC (US) | 2009-11-04 | — | — | EP | disclosed |
| US-7582765-B2 | Aryl aniline β2 adrenergic receptor agonists | THERAVANCE, INC. (US) | 2009-09-01 | — | — | US | disclosed |
| US-20070225329-A1 | Aryl aniline beta2 adrenergic receptor agonists | THERAVANCE BIOPHARMA R&D IP, LLC | 2007-09-27 | — | — | US | disclosed |
| EP-1641465-A2 | COMBINATIONS OF AN ARYL ANILINE BETA-2 ADRENERGIC RECEPTOR AGONIST AND A CORTICOSTEROID | Theravance, Inc. (US) | 2006-04-05 | — | — | EP | disclosed |
| WO-2005025555-A2 | COMBINATIONS OF AN ARYL ANILINE BETA-2 ADRENERGIC RECEPTOR AGONIST AND A CORTICOSTEROID | THERAVANCE, INC. (US) | 2005-03-24 | — | — | WO | disclosed |
| US-20030229058-A1 | Aryl aniline beta2 adrenergic receptor agonists | THERAVANCE BIOPHARMA R&D IP, LLC | 2003-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10065965-B2 | Imidazo[1,2-B][1,2,4]triazine derivatives as antiparasitic agents | HDAC1, HDAC11, HDAC5 | ALDH1A1 186/4885HTT 843/4885KDM4E 2317/4885 |
| US-20070225329-A1 | Aryl aniline beta2 adrenergic receptor agonists | ADRB2, ADRB3, ADRB1 | ALDH1A1 614/4885HTT 3363/4885KDM4E 4025/4885 |
| US-20180141949-A1 | IMIDAZO[1,2-B][1,2,4]TRIAZINE DERIVATIVES AS ANTIPARASITIC AGENTS | HDAC1, HDAC11, HDAC5 | ALDH1A1 186/4885HTT 843/4885KDM4E 2317/4885 |
| US-20030229058-A1 | Aryl aniline beta2 adrenergic receptor agonists | ADRB2, ADRB1, ADRB3 | ALDH1A1 397/4885HTT 3493/4885KDM4E 4101/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.